This page shows the latest PPMS news and features for those working in and with pharma, biotech and healthcare.
Primary-progressive MS (PPMS) accounts for about 10-15% of MS cases and is characterised by a fairly steady, gradual change in functional ability over time without any remissions.
The trial is a first-of-its-kind, open-label, phase 3b study evaluating the effect of Ocrevus in SPMS and PPMS patients. ... For 75% of patients diagnosed with SPMS and PPMS treated with Ocrevus, they showed no evidence of progression (NEP) after one year
The post-hoc analysis of the ORATORIO study also showed that Ocrevus treatment slowed accumulation of atrophied T2-lesion volume (aT2-LV) compared with placebo at 120 weeks in PPMS. ... According to Roche, those living with PPMS experience three to five
The agreement means NICE can now reverse the rejection it announced in November, and Ocrevus(ocrelizumab), will be fully available to patients with primary progressive multiple sclerosis (PPMS) in England, the ... England's contribution to its revenues
and NICE to reach an agreement that will allow the drug to be covered for PPMS. ... We ask that NICE are given the flexibility to consider an indication-specific price for ocrelizumab in PPMS.”.
NICE says no to Ocrevus in primary progressive MS. On Friday NICE announced that it would not recommend Roche; s Ocrevus (ocrelizumab) for treating primary progressive multiple sclerosis (PPMS) in adults. ... Ocrevus is the only drug approved for PPMS,
More from news
Approximately 2 fully matching, plus 9 partially matching documents found.
No results were found
Wisepress is a medical bookseller promoting and selling books worldwide, both online and via the 200 European medical conferences that...